SCHEMBL30407947

CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)[C@@H](C)O)[C@@H](C)CC)C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 4)

	gene	UniProt	supporting neighbours	confidence
▸	OPRM1	P35372	5/20	0.55

▸	OPRD1	P41143	5/20	0.55

▸	GLP1R	P43220	15/20	0.54

▸	OPRK1	P41145	4/20	0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL31256793	0.99	OPRM1 (0.55)	OPRM1OPRD1GLP1ROPRK1
SCHEMBL30636778	0.96	GLP1R (0.55)	OPRM1OPRD1GLP1ROPRK1
SCHEMBL30299020	0.95	GLP1R (0.58)	OPRM1OPRD1GLP1ROPRK1
SCHEMBL31030934	0.95	GLP1R (0.57)	OPRM1OPRD1GLP1ROPRK1
SCHEMBL30918524	0.94	GLP1R (0.58)	OPRM1OPRD1GLP1ROPRK1
SCHEMBL31256795	0.94	OPRM1 (0.57)	OPRM1OPRD1GLP1ROPRK1
SCHEMBL30169866	0.93	GLP1R (0.50)	OPRM1OPRD1GLP1ROPRK1
SCHEMBL30368416	0.93	OPRM1 (0.56)	OPRM1OPRD1GLP1ROPRK1
SCHEMBL30080556	0.91	OPRM1 (0.61)	OPRM1OPRD1GLP1ROPRK1
SCHEMBL31258952	0.91	OPRD1 (0.57)	OPRM1OPRD1GLP1ROPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20230143604-A1	QW DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF	TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)	2023-05-11	—	—	US	claimed
US-20230143604-A1	QW DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF	TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)	2023-05-11	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20230143604-A1	QW DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF	GIPR, GLP1R, GRPR	OPRM1 290/4885OPRD1 272/4885GLP1R 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.